INFI News and Press, Infinity Pharmaceuticals Inc. From 12/13/21

Infinity is being highlighted as part of B. Riley’s Fall 2021 Growth Biotech “Best Ideas” research series including an interactive discussion with KOL, Hatem Soliman, MD Virtual fireside chat scheduled for Tuesday, December 14 th @ 2:30pm ET ...

Announcing updated data from its ongoing MARIO-3 clinical study, Infinity Pharmaceuticals (NASDAQ:INFI) said that its combination therapy consisting of eganelisib, for metastatic breast cancer, led 88.6% of patients to show tumor reduction. The Phase 2 trial was designed to evaluate eganelisi...

Context Therapeutics (NASDAQ:CNTX) +25% on positive ONA-XR data in early breast cancer study. American Virtual Cloud Technologies (NASDAQ:AVCT) +25% Kandy and Braidio announce expanded partnership to accelerate the delivery of digital transformation as a service solutions. Ener...

-88.6% of Evaluable 1L TNBC Patients Achieved Tumor Reduction- -Disease Control Rate of 92.8% and 81.4% of Evaluable Patients with PD-L1 Positive and PD-L1 Negative Tumors, Respectively- -Median PFS Improvement of 47% and 30% Compared to IMpassion130 Benchmark for Pati...

MARIO-3 Phase 2 study evaluating eganelisib added to standard of care Tecentriq® and Abraxane® regimen in frontline triple negative breast cancer (TNBC) Investor Event with KOL Scheduled for Friday, December 10 th @ 9:30am ET Infinity Pharmaceuticals,...

Today we tee up a small 'off the radar' oncology concern called Infinity Pharmaceuticals for some in-depth research. The company posted encouraging trial results in July and is working with large drug makers to establish its primary candidate as part of combo therapies. A full inv...

Infinity Pharmaceuticals, Inc . (NASDAQ: INFI), a clinical-stage biotechnology company developing eganelisib, a potentially first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic which addresses a fundamental biologic mechanism of immune suppression in cancer, to...

Infinity Pharmaceuticals, Inc. (INFI) Q3 2021 Earnings Conference Call November 2, 2021 4:30 PM ET Company Participants Jayne Kauffman - Senior Administrative Manager Adelene Perkins - Chair and Chief Executive Officer Robert Ilaria - Chief Medical Officer Larry Bloch - President Conference C...

Infinity Pharmaceuticals (NASDAQ:INFI): Q3 GAAP EPS of -$0.12 beats by $0.01. Revenue of $0.43M (-14.0% Y/Y) misses by $0.11M. Shares +1%. Press Release Financial Outlook: Infinity’s 2021 financial guidance remains as follows: Net Loss: Infinity expects net loss for 2021 to range from ...

ADC, AFG, DADA, AIZ, AKAM, AMCR, AMED, AMGN, ANDE, APPS, AQST, ATVI, AWK, AYX, BFAM, BGFV, BKH, BTG, BXC, CASA, CDK, CDLX, CERS, CGBD, CHCT, CHK, CLW, COUR, CRK, [CSLT]], CVGI, CZR, DCP, DCPH, DENN, DHT, DOX, DRRX, [DVN]], EARN, EGHT, EIX, EKSO, ELVT, ENLC, EXAS, EXEL, FMC, FNF, FRG, GAIN, GN...